Research Article
Characterization and miRNA Profiling of Extracellular Vesicles from Human Osteoarthritic Subchondral Bone Multipotential Stromal Cells (MSCs)

Clara Sanjurjo-Rodríguez,1,2,3 Rachel E. Crossland,1 Monica Reis,1,4 Hemant Pandit,2,5 Xiao-nong Wang,1 and Elena Jones2

1Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK
3Cell Therapy and Regenerative Medicine Group, Physiotherapy, Medicine and Biomedical Sciences Department, Universidade da Coruña, A Coruña 15006, Spain
4Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
5Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA, UK

Correspondence should be addressed to Xiao-nong Wang; x.n.wang@newcastle.ac.uk and Elena Jones; e.jones@leeds.ac.uk

Received 20 April 2021; Revised 26 July 2021; Accepted 19 August 2021; Published 9 October 2021

Copyright © 2021 Clara Sanjurjo-Rodríguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteoarthritis (OA) is a heterogeneous disease in which the cross-talk between the cells from different tissues within the joint is affected as the disease progresses. Extracellular vesicles (EVs) are known to have a crucial role in cell-cell communication by means of cargo transfer. Subchondral bone (SB) resident cells and its microenvironment are increasingly recognised to have a major role in OA pathogenesis. The aim of this study was to investigate the EV production from OA-MSCs, characterized and cocultured with chondrocytes for viability and gene expression analysis, and compared to small EVs from MSCs of healthy donors (H-EVs). OA-EVs enhanced viability of chondrocytes and the expression of chondrogenesis-related genes, although the effect was marginally lower compared to that of the H-EVs. miRNA profiling followed by unsupervised hierarchical clustering analysis revealed distinct microRNA sets in OA-EVs as compared to their parental MSCs or H-EVs. Pathway analysis of OA-EV miRNAs showed the enrichment of miRNAs implicated in chondrogenesis, stem cells, or other pathways related to cartilage and OA. In conclusion, OA SB MSCs were capable of producing EVs that could support chondrocyte viability and chondrogenic gene expression and contained microRNAs implicated in chondrogenesis support. These EVs could therefore mediate the cross-talk between the SB and cartilage in OA potentially modulating chondrocyte viability and endogenous cartilage regeneration.

1. Introduction

Osteoarthritis (OA) is a heterogeneous disease that affects synovial joints, which starts from injury or as a molecular alteration and results in structural changes, such as loss of cartilage, bone sclerosis or osteophyte formation, pain, and other clinical symptoms [1]. OA is one of the most prevalent joint diseases and frequently causes disability, with high incidence worldwide due to population aging [2–4].

Early OA changes in articular cartilage include regional proteoglycan loss, chondrocyte clustering, collagen disorganization, and tissue fibrillation [5]. While the catabolic/anabolic imbalance in bone is associated to overloading microdamages, in cartilage it seems to be associated with persistent, low-grade inflammation [6]. It begins in the synovial tissue where it is characterized by cytokine release and immune cell infiltration and is commonly associated with pain in OA [7, 8]. With OA progression, subchondral
Bone (SB) gains more influence on OA chondrocytes as osteochondral junction becomes more porous [5, 6, 9–13]. Bone-targeting treatments have a positive effect on OA chondrocytes [6] while cocultures of OA subchondral bone osteoblasts [10] or osteoclasts [14] with OA chondrocytes have a negative effect on chondrocytes’ viability or anabolic activity. The bone-cartilage cross-talk is therefore emerging as a novel therapeutic target for OA [13, 15].

In OA, different types of SB cells enter normally the nonvascular calcified cartilage through the cracks and fissures or along the newly formed vessels, all contributing to cartilage destruction “from below” [12, 16–18]. These SB cells include osteo/chondroclasts that dissolve the calcified cartilage matrix [18, 19], neurons that exacerbate joint pain [13, 20, 21], and multipotential stromal cells (MSCs) that may be involved in both, cartilage formation and cartilage degradation [12, 18]. Besides the cells themselves, SB-cartilage communication in OA may be mediated via soluble proteins [22], for example, VEGF or IL6, which are increased in damaged SB areas in OA [23], and or via extracellular vesicles (EVs); the influence of which on OA chondrocyte homeostasis remains poorly understood [24].

EVs are nonreplicative bilipid-layered particles that are released naturally from most of the cells, carrying peptides, miRNAs, lipids, and other molecules in their cargo, which can be transmitted to other cells. They can be broadly subcategorised based on their biogenesis, size, and markers into exosomes, microvesicles, and apoptotic bodies [25–27]. EVs have a crucial role in cell-to-cell communication, allowing the cargo transfer through endocytic internalization or direct fusion to provoke a biological response [28–31]. Recently, studies of EVs in joint diseases and their therapeutic use started to rise [24, 32–35], but these studies are primarily focused on EVs derived from osteoarthritic synovial fluid rather than SB [36, 37].

The aim of this study was to investigate EV production from SB MSCs, the cells previously shown to contribute to disease pathogenesis in OA [18, 38, 39]. We hypothesised that SB MSC-EVs may have an influence on OA chondrocytes’ viability and their anabolic gene expression and that they contain specific sets of miRNAs that are different from their parental MSCs.

2. Materials and Methods

2.1. Patients and Cells. Ethical approval for cartilage and MSC osteoarthritic sample collection was obtained from the NRES Committees Yorkshire & The Humber—South Yorkshire (14/YH/0087) and NRES Committees North East—Newcastle & North Tyneside 1 (14/NE/1212). From this collection, 11 cartilage samples (6 females and 5 males with median age 74 years, range 55–83) and 5 subchondral bone samples (3 females and 2 males with median age 73 years, range 64–83) were collected from total knee arthroplasty. Patients were 7 males and 3 females with the median age of 14 years (range 4–44).

2.2. Isolation and Culture of OA Chondrocytes. Articular cartilage was harvested from tibiofemoral surfaces, and chondrocytes were isolated as previously described [18]. Briefly, the cartilage was harvested and minced using a scalpel and digested with collagenase overnight. Chondrocytes were expanded in a high-glucose Dulbecco’s Modified Eagle Medium (DMEM; MilliporeSigma, USA) supplemented with glutamine, 10% fetal bovine serum (FBS; ThermoFisher Scientific, USA), and 1% penicillin/streptomycin (P/S; MilliporeSigma, USA). Media were changed twice a week, and subculture was performed when chondrocytes reached 80% confluence, and passed to passage 2 (p2).

2.3. Isolation and Culture of MSCs. Osteoarthritic MSCs were obtained from the subchondral bone of medial femoral condyles after removal of cartilage, as previously described [18]. Medial condyles were chosen as they commonly display a more prominent OA phenotype compared to lateral condyles [18, 40]. Bone was weighed and mechanically minced into small fragments with a rongeur and digested with collagenase, as previously described [18]. MSC cultures were established in StemMACS™MSC expansion media (Miltenyi Biotech, Germany) then transferred to DMEM supplemented with 5% human platelet lysate (PL; PLTMax, MilliporeSigma), 100 IU/ml penicillin, 100μg/ml streptomycin, 2,500 IU/ml heparin and 2mM-glutamine (all from MilliporeSigma) 5%PL/DMEM.

Healthy control MSCs were cultured from surplus cells (wash-outs) of hematopoietic stem cell transplantation bags, as previously described [41]. Briefly, bone marrow mononuclear cells (MNCs) were isolated by density gradient centrifugation and cultured in 5%PL/DMEM.

Both types of MSCs were previously characterized [18, 41] (Supplementary Figures 1 and 2) according to the criteria set by the International Society of Cellular Therapy (ISCT) [42] and expanded in 5%PL/DMEM to passage 3 before changing the media to EV-depleted 5%PL/DMEM, for EV isolation. EV-depleted MSC media were prepared by 18-hour ultracentrifugation of 10%PL/DMEM at 100,000 × g followed by 1:1 dilution in DMEM.

2.4. EV Isolation from OA and Control MSCs. EVs were isolated from both osteoarthritic (OA-EVs) and control healthy (H-EVs) p3 MSCs, as previously described [41]. In brief, when the cells reached 50% confluence, they were washed three times with phosphate buffered saline (PBS, MilliporeSigma) and cultured in a 5%PL/DMEM-EV-depleted medium, for a further duration of 48 hours prior to harvesting the conditioned media and MSC-EV isolation. In addition to collecting the conditioned medium, the number of MSCs in the flask was counted and an aliquot of cells was frozen as pellets in a QIAzol lysis reagent (Qiagen, Germany) for RNA isolation. To obtain MSC-EVs, the conditioned medium was centrifuged at 400 × g for 5 min, 2,000 × g for 20 min at 4°C, then transferred to ultracentrifuge tubes (Beckman Coulter, USA) and centrifuged again sequentially at 10,000 × g for
2.5. MSC-EV Characterization. MSC-EV characterization was performed by electron microscopy (TEM), flow cytometry, and nanoparticle tracking analysis (NTA) [41].

For TEM, 5 μl of MSC-EVs was adsorbed for 30 s onto a carbon-coated, glow-discharged grid. Excess liquid was removed and samples were stained with 1% uranyl acetate (Agar Scientific, UK). Excess uranyl acetate solution was removed, and the MSC-EV-loaded grids were dried then examined using a Hitachi HT7800 transmission electron microscope. Digital images were collected using an Emsis Xarosa camera with Radius software. The acquired data was processed using NTA 2.3 software (Tecan). For TEM, 5 μl of MSC-EVs was adsorbed for 30 s onto a carbon-coated, glow-discharged grid. Excess liquid was removed and samples were stained with 1% uranyl acetate (Agar Scientific, UK). Excess uranyl acetate solution was removed, and the MSC-EV-loaded grids were dried then examined using a Hitachi HT7800 transmission electron microscope. Digital images were collected using an Emsis Xarosa camera with Radius software. The acquired data was processed using NTA 2.3 software (Tecan).

EV surface markers CD63, CD9, and CD81 were analyzed by flow cytometry following coating of 4 μm aldehyde/sulfate latex beads (ThermoFisher Scientific) with 10 μl of MSC-EVs suspension. The reaction was stopped by incubation with 1 M glycine (MilliporeSigma), and the MSC-EV-bead complex was washed twice with PBS then incubated with mouse anti-human PE CD63 (clone H5C6), PerCP-Cy5.5 CD9 (clone M-L13), and APC CD81 (clone JS-81) antibodies or corresponding isotype controls (all from BD Biosciences, USA). Following further washes, cells were resuspended in particle-free PBS (ThermoFisher Scientific) and data was acquired using a BD FACS Canto II cytometer (BD Biosciences) and analyzed with FlowJo 10.0 software (Tree Star Inc., USA).

For NTA, MSC-EV pellets were diluted with sterile particle-free PBS and analyzed using Nanosight LM10 (Malvern Panalytical Ltd, UK), as described by the manufacturer’s protocol. Three 60 s measurements of the particle size and concentration were measured for each sample. The acquired data was processed using NTA 2.3 software (Malvern Panalytical Ltd).

2.6. ATP-Based Viability Assessment of Chondrocytes following Coculture with MSC-EVs. The CellTiter-Glo 2.0 Luminiscent Cell Viability Assay (Promega, UK) measures total ATP levels produced by metabolically active cells. For this assay, EV-depleted chondrocyte media was first prepared by 18-hour ultracentrifugation of DMEM/Nutrient Mixture F-12 (DMEM:F12, ThermoFisher Scientific) containing 10% FBS (DMEM:F12/10%FBS) at 100,000 × g and centrifuged at 450 × g for 10 min to create 3D pellets, for each treatment. In addition, 2 × 10^5 chondrocytes were pelleted in EV-depleted DMEM:F12/10%FBS media without MSC EVs and used as negative controls (No EVs). After 2 and 7 days, EV-depleted media was half-changed and cell pellets were taken for RNA isolation. In these experiments, OA-EVs and H-EVs were from 2 different donors each, and the chondrocyte cultures (n = 3) were not donor-matched to OA-MSCs. Longer-term effect of OA and healthy MSC-EVs on chondrocyte gene expression in the pellet culture was tested using a single-donor chondrocyte culture and MSC to chondrocyte ratio of 4:1, with half-change medium every 3-4 days.

2.7. Three-Dimensional (3D) Pellet Coculture of MSC-EVs and OA Chondrocytes. To characterize whether MSC-EVs (both OA- and H-EVs) have an effect on chondrocytes’ expression of genes implicated in the extracellular matrix (ECM) metabolism, EVs from 6 × 10^6 OA or control MSCs were added to 6 × 10^5 chondrocytes resuspended in EV-depleted DMEM:F12/10%FBS media (MSC-EVs to chondrocytes ratio 10:1). Afterwards, chondrocytes were separated into 3 different tubes and centrifuged at 450 × g for 10 min to create 3D pellets, for each treatment. In addition, 2 × 10^5 chondrocytes were pelleted in EV-depleted DMEM:F12/10%FBS media without MSC EVs and used as negative controls (No EVs). After 2 and 7 days, EV-depleted media was half-changed and cell pellets were taken for RNA isolation. In these experiments, OA-EVs and H-EVs were from 2 different donors each, and the chondrocyte cultures (n = 3) were not donor-matched to OA-MSCs.

2.8. RNA Isolation from OA and Healthy MSC-EVs, Parental MSCs, and MSC-EV-Treated Chondrocytes. For isolation of RNA from EVs (60 μl of the EVs suspension in PBS), total Exosome RNA and Protein Isolation kit (ThermoFisher Scientific) were used following the manufacturer’s instructions. The RNA concentration from EVs was assessed using the Bioanalyzer 2100 and the RNA 6000 pico kit (Agilent Technologies, USA).

RNA from parental MSCs (from which EVs were produced from) and from chondrocyte pellets was obtained using the miRNeasy Mini kit (Qiagen) following the manufacturer’s instructions. The RNA was quantified using the Nanodrop spectrophotometer (ThermoFisher Scientific).

2.9. miRNA Profiling from OA and Healthy MSC-EVs. miRNA profiling was carried out using the nCounter® Human v3.0 miRNA Expression Assay Kit (NanoString Technologies), based on miRBase v21, from total RNA obtained from OA-EVs and H-EVs as well as parental MSCs (the MSCs from which the respective EVs were obtained from). The code set incorporated 799 mature microRNAs and included 6 positive controls, 8 negative controls, 6 ligation controls, 5 mRNA housekeeping controls (ACTB, B2M, GAPDH, RPL19 and RPLP0) and 5 spike-in controls. miRTag ligation, miRNA CodeSet Hybridization and post-hybridization were performed following the manufacturer’s instructions. The resulting miRNA expression profiles were...
analyzed using the nSolver software V4 (NanoString Technologies). Samples were normalized to the geometric mean of the Top100 miRNAs taking into account background thresholding and positive control normalization (geometric mean). Fold change (FC) expression differences between groups were calculated using nSolver v2.5 (NanoString Technologies) ratio data, based on normalized count data. Further analysis was performed using a pipeline designed by Newcastle University, Haematological Sciences Department. This integrated a number of R (R project) statistical packages in the R programming language; p values between two groups were generated using a two-tailed t-test. Analysis on miRNA targets was performed using mirWalk [44], mir-Path from DIANA Tools [45], Reactome [46] and miRDIP [47], utilizing default parameters for Human or Homo sapiens.

2.10. Quantitative Real Time PCR. Gene expression was assessed in 2, 7, and 21 day-cultured OA and healthy MSC-EV-treated pellets and control chondrocyte pellets. Total RNA was isolated and reverse transcribed with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). qRT-PCR was performed using the Taqman assays (ThermoFisher Scientific; Table 1) and Fast Advanced Master Mix (Applied Biosystems, ThermoFisher Scientific) in a QuantStudio 3 Real-Time PCR system (Applied Biosystems). Genes for the analysis were selected based on the literature evidence of their involvement in the chondrogenesis and chondrocyte catabolic and anabolic activity [12, 48] and are shown in Table 1.

3. Results

3.1. EV Characterization. EVs isolated from OA-MSCs (n = 5) showed similar basic characteristics (Figure 1) than previously shown for control healthy MSCs [41]. Expression of different markers of small EVs [25] in OA-EV preparations was first tested using flow cytometry (Figure 1(a)). CD63 (95.9% ± 7.4%) and CD81 (90.1% ± 13.0%) were the highest expressed markers followed by CD9 (66.1% ± 23.8%) indicating presence of small EVs (Figure 1(a)). The morphology of OA-EVs observed using TEM was a typical cup-shape (Figure 1(b)). The concentration of particles and the size of the EVs was measured using NTA (Figure 1(c), Table 2). The mode of the OA-EV size ranged between 107.9-169.8 nm (Table 2) not significantly different to H-EVs (81.3-132.9), and consistent with the modal size previously reported for control H-EVs [41]. The mean concentration of particles per ml in OA-EV preparations was $1.38 \times 10^{11} \pm 2.07 \times 10^{10}$ and is similar to that of the H-EVs (1.12 x 10^{11} ± 8.50 x 10^{10}) (Table 2). As cell number was counted after OA and healthy MSC-EV media collection, no differences (p > 0.05) were found in the mean number of particles obtained per cell from either OA or control MSCs: 634 ± 176 and 709 ± 447, respectively. Neither difference was observed when comparing mean EV size between healthy and OA-MSC-EVs (p > 0.05): 112.7 ± 23.50 nm and 138.2 ± 25.68 nm, respectively, but OA-EVs seemed less variable than H-EVs (Figure 1(c)). These data indicated that OA-MSCs had a similar capacity to produce EVs with a comparable modal size and particle concentration as control healthy MSCs.

3.2. The Effects of OA and Healthy MSC-EVs on Chondrocyte Viability. An ATP-based viability assessment was performed following coculture of OA chondrocytes with OA- or H-EVs. When comparing untreated chondrocytes with those treated with control H-EVs, an average 6.27% increase in chondrocyte viability was found (p value = 0.020) (Figure 2(a)). OA-EV treated chondrocytes also showed increased viability compared to untreated chondrocytes (average 5.92%, p value = 0.042) (Figure 2(b)). However, the difference in the percentage increase of viability between OA and H-EVs failed to reach statistical significance (p value = 0.768) (Figure 2(c)).

3.3. The Effects of OA and Healthy MSC-EVs on Chondrocyte Gene Expression. In these experiments, pellet culture of chondrocytes and EVs was used to facilitate EV uptake by chondrocytes, as reported previously [49]. The media used in these experiments did not contain any chondrogenic inducers because the latter could ‘mask’ potentially smaller effects by EVs. To confirm that pellet culture environment was sufficient to induce chondrogenic gene up-regulation in chondrocytes, and to investigate how it affected the expression of the selected catabolic and anabolic genes, a time-course experiment in untreated pelletted chondrocytes from 4 donors was performed (Figure 3(a)).

As expected, gradual increases in chondrogenesis markers SOX9, COL2 and ACAN, as well as COL1, were seen from day 2 onwards confirming that pellet culture in the
Figure 1: OA-MSC-EV characterization. (a) Flow cytometry of CD63, CD9, and CD81 surface markers (representative OA-EV sample). Red and blue histograms illustrate isotype controls and stained samples, respectively. (b) Transmission Electron Microscopy showing the cup-shape morphology of EVs (representative OA-EV sample, scale bar 200 nm). (c) Scatter plot showing size and number of particles/cell analysis of OA and control H-EVs, assessed by nanoparticle tracking analysis.
absence of chondrogenic inducers was sufficient to monitor the effect of EVs on chondrogenic gene up-regulation. The up-regulation of other transcripts (MMP13, ADAMTS4 and ADAMTS5) did not similarly continue beyond day 7 (Figure 3(a)).

An average 18% up-regulation of SOX9 transcript compared to untreated chondrocytes was observed in coculture with H-EVs and the effect was smaller (average 4% increase) in coculture with OA-EVs however the differences failed to reach statistical significance (Figure 3(b)). A trend for lower-level upregulation of SOX9 by OA-EVs compared to H-EVs, as well as of transcripts for mature cartilage ECM proteins COL2 and ACAN was evident following longer-term culture (Figure 3(c)). Higher COL2/COL1 ratio indicating chondrogenic lineage commitment displayed the same trend, unlike the expression of cartilage catabolic molecules where no specific trends were found (both short- and long-term) (Figure 3(c)).

### miRNA Profiling

3.4. miRNA Profiling. Albeit not being statistically significant, average of 1.5-fold differences in chondrocytes’ chondrogenesis gene expression (SOX9, COL2 and ACAN expression at 21 days), indicated potential differences in microRNA cargo between H-EVs and OA-EVs. microRNA expression profiling was next performed on H-EVs and OA-EVs (n = 4 cultures each) using NanoString technology (n = 799 microRNA). Expression of 590 mature microRNAs was detected across all samples after correcting for background (Supplementary Data 1). Healthy and OA-EVs showed distinct microRNA expression profiles, as demonstrated using unsupervised hierarchical clustering analysis (Figure 4). There were 75 miRNAs that were significantly

| Sample   | Mean (nm) | Particle size SD (nm) | Mode (nm) | Concentration of particles | Particles/ml* | Particles/frame* | Particles/cell* |
|----------|-----------|------------------------|-----------|----------------------------|---------------|-----------------|-----------------|
| OA-EV1   | 161.6     | 69.3                   | 169.8     | 1.19 × 10^{11} ± 1.64 × 10^{10} | 12.1 ± 1.7   | 692 ± 95        |
| OA-EV2   | 172.2     | 75.0                   | 121.1     | 1.30 × 10^{11} ± 1.69 × 10^{10} | 13.2 ± 1.7   | 531 ± 69        |
| OA-EV3   | 177.2     | 87.4                   | 158.4     | 1.15 × 10^{11} ± 1.07 × 10^{10}   | 11.7 ± 1.1   | 622 ± 58        |
| OA-EV4   | 160.0     | 71.6                   | 133.7     | 1.35 × 10^{11} ± 3.20 × 10^{10}   | 13.7 ± 3.2   | 433 ± 103       |
| OA-EV5   | 172.0     | 71.1                   | 107.9     | 1.92 × 10^{11} ± 2.75 × 10^{10}   | 29.2 ± 4.2   | 897 ± 128       |
| H-EV1    | 184.1     | 89.4                   | 132.9     | 2.36 × 10^{11} ± 2.53 × 10^{10}   | 77.4 ± 8.1   | 3670 ± 393      |
| H-EV2    | 152.3     | 67.4                   | 110.2     | 7.43 × 10^{10} ± 4.76 × 10^{8}    | 61.7 ± 4.0   | 1265 ± 81       |
| H-EV3    | 125.2     | 52.9                   | 100.7     | 5.58 × 10^{10} ± 2.9 × 10^{9}     | 27.2 ± 1.5   | 1240 ± 64       |
| H-EV4    | 154.8     | 63.6                   | 107.9     | 9.41 × 10^{10} ± 1.11 × 10^{10}   | 46.7 ± 5.7   | 752 ± 88        |
| H-EV5    | 129.6     | 55.3                   | 81.3      | 5.76 × 10^{10} ± 3.32 × 10^{9}    | 21.6 ± 1.4   | 694 ± 40        |
| H-EV6    | 152.1     | 79.7                   | 98.4      | 1.53 × 10^{11} ± 3.59 × 10^{9}    | 77.7 ± 2.2   | 3035 ± 71       |

*Data shows mean ± SD from measurements of 3 different frames within the Nanosight.
Figure 3: Gene expression of characteristic cartilage catabolic and anabolic genes measured in (a) untreated chondrocytes (no EVs) cultured for 2, 7, and 21 days. Horizontal bars show medians, and whiskers represent interquartile range. (b) SOX9 expression in untreated and H-EV or OA-EV treated chondrocytes after 2 and 7 days. Symbols represent individual donor-derived chondrocyte cultures. (c) Chondrogenic gene expression in untreated (no EVs) and treated (H-EVs and OA-EVs) chondrocytes after 2, 7, and 21 days.
differentially expressed between H-EVs and OA-EVs, of which 48 retained significance after FDR correction. A total of 47 were upregulated in healthy EVs and 1 in OA-EVs (fold change (FC) range = −12.3 – 26.67, p value range = 0.002-0.037) (Figure 4).

The 48 DE-expressed microRNAs were predicted to target KEGG pathways [50] using mirPath [45], with key implications in chondrogenesis or stem cells, including extracellular matrix interaction (56 genes, 36 microRNAs, p < 0.001), N-glycan biosynthesis (30 genes, 29 microRNA, p < 0.001), focal adhesion (133 genes, 43 microRNAs, p < 0.001) and signalling pathways regulating pluripotency of stem cells (94 genes, 45 microRNAs, p < 0.001). Predicted gene targets identified with ‘very high’ score class (top 1%) via the microRNA Data Integration Portal (mirDIP) were filtered for duplicates, resulting in 10,755 unique gene targets. Reactome pathways implicated by the target genes included cell-cell communication (95/133 genes), transcriptional regulation of pluripotent stem cells (38/45 genes), extracellular matrix organisation (207/329 genes), transport of small molecules (483/967 genes), and vesicle-mediated transport (510/824 genes). miRWalk also predicted target map to signalling pathways “regulating pluripotency of stem cells” pathway.

In addition to microRNAs that were significantly differentially expressed between OA-EVs and H-EVs, we also assessed the top 20 most highly expressed microRNAs in each population, as well as those that were commonly highly expressed in both OA and H-EVs. 17 microRNA were expressed at a high level in both populations, while miR-6721-5p, miR-579-3p and miR-199a-5p were uniquely highly expressed in OA-MSC-EVs, and miR-145-5p, miR-126-3p and miR-15b-5p were uniquely highly expressed in control healthy MSC-EVs (Table 3).

When we compared miRNAs in OA-EVs with their parental MSCs (Supplementary Data 2), we found that they clustered separately (Figure 6). There were 130 miRNAs that...
were significantly differentially expressed between OA-EVs and parental OA-MSCs, of which 124 retained significance after FDR correction (Figure 6). A total of 120 were upregulated in healthy EVs and 4 in OA-EVs (fold change (FC) range = −7.95 – 68.62, p value range ≤ 0.001-0.049) (Figure 4).

For KEGG pathway analysis [50], 100 miRNA with higher FC out of the 124 DE expressed microRNAs were analyzed using mirPath [45]. The same key implications in chondrogenesis or stem cells were found as above, with the exception of pathways regulating pluripotency of stem cells: extracellular matrix receptor interaction (71 genes, 77 microRNAs, p < 0.001), N-glycan biosynthesis (44 genes, 58 microRNA, p < 0.001) and focal adhesion (177 genes, 82 microRNAs, p < 0.001). Other pathways observed were proteoglycans in cancer (180 genes, 80 microRNAs, p < 0.001), fatty acid metabolism (42 genes, 66 microRNAs, p < 0.001) or cell cycle (111 genes, 77 microRNAs, p < 0.001). Predicted gene targets with ‘very high’ score class (top 1%) via the microRNA Data Integration Portal (mirDIP) were identified, resulting in 100,714 unique gene targets. Reactome pathways implicated by the target genes included MECP2 regulated neuronal receptors and channels (32/32), transcription factor forhead box O (FOXO)-mediated transcription (85/110 genes), TP53 regulated transcription of genes involved in G1 cell cycle arrest (20/20), transcriptional regulation by RUNX family transcription factor 3 (RUNX3) (87/118 genes), extracellular matrix organization (249/329 genes), programmed cell death (170/238 genes), and vesicle-mediated transport (552/824 genes). miRWalk predicted target map to signalling pathways related to cartilage and osteoarthritis as “glycolysis gluco-neogenesis”, “fatty acid metabolism”, “glycosaminoglycan biosynthesis”, “autophagy”, “FOXO signaling pathway”, “calcium signaling pathway”, “osteoclast differentiation”, and other pathways like “endocytosis” or “cell cycle”.

Assessing the top 20 most highly expressed microRNAs, 14 microRNAs were expressed at a high level in both parental OA-MSCs and their EVs, while 6 miRNAs were uniquely highly expressed in OA-MSC-EVs and other 6 were uniquely highly expressed in parental MSCs (Table 4).

### Table 3: microRNAs highly expressed in OA-EVs and control H-EVs.

| Names                  | Total microRNAs |
|------------------------|-----------------|
|                        | hsa-miR-142-3p  |
|                        | hsa-miR-199a-3p + hsa-miR-199b-3p |
|                        | hsa-miR-4286    |
|                        | hsa-let-7a-5p   |
|                        | hsa-miR-16-5p   |
|                        | hsa-miR-21-5p   |
|                        | hsa-miR-29a-3p  |
|                        | hsa-miR-29b-3p  |
|                        | hsa-let-7i-5p   |
|                        | hsa-miR-4454+   |
|                        | hsa-miR-7975    |
|                        | hsa-miR-630     |
|                        | hsa-let-7b-5p   |
|                        | hsa-miR-221-3p  |
|                        | hsa-miR-23a-3p  |
|                        | hsa-miR-100-5p  |
|                        | hsa-miR-125b-5p |
|                        | hsa-miR-223-3p  |
|                        | hsa-miR-6721-5p |
|                        | hsa-miR-579-3p  |
|                        | hsa-miR-199a-5p |
| **Shared OA-EVs & H-EVs** | 17              |
|                        | hsa-miR-145-5p  |
|                        | hsa-miR-126-3p  |
|                        | hsa-miR-15b-5p  |
| **OA-EVs**             | 3               |
|                        | hsa-miR-145-5p  |
|                        | hsa-miR-126-3p  |
|                        | hsa-miR-15b-5p  |
| **H-EVs**              | 3               |


4. Discussion

Previous studies on EVs in OA have almost exclusively focused on the synovial fluid (SF) EVs, which mediate the cross-talk between the damaged cartilage and the inflamed synovium [51, 52] and have shown their considerable influence on chondrocyte catabolism, senescence, and death [53–57]. In contrast, the cross-talk between subchondral bone (SB) cells and chondrocytes in OA is comparatively less explored, despite the fact that SB pathology is implicated in all stages of OA progression [13, 58, 59]. Furthermore, in previous studies of SF-resident EVs, their tissues of origin, as well as the cells of origin, remained unknown. In contrast, our study is uniquely focused on the cross-talk between cartilage and SB in OA and investigated EV production from a specific type of SB cells, SB MSCs, which are directly implicated in SB OA pathology and cartilage destruction “from below” [60–62]. Although SB MSCs from healthy amputees would be a better control than the MSCs from bone marrow used in this work, these samples are difficult to access while MSCs from amputated knees from diabetics could carry underlying negative effects such as described previously [63–65].

In this work, when comparing EV size and yields (particle/cell) released from OA and control healthy MSCs, no differences were found, similar to results previously described for healthy and OA-EVs from SF [55, 57]. Previous works on SF-EVs have presented slightly lower EV sizes [53–55], which could be explained by different methods used for EV isolation in these studies: using ultracentrifugation combined with precipitation [54, 55] or using immunoaffinity [53]. EVs obtained from ultracentrifugation alone, as was in our study, are known to be less purified due to the overlap in sizes between EVs and microvesicles [25], however ultracentrifugation is less harmful for EVs [66].

One of the principal aims of this study was to identify specific sets of miRNAs in the OA-EVs derived from SB-MSCs. Depending on the cell of origin, EVs (including exosomes) can contain many constituents of a cell including DNA, RNA, lipids, metabolites, and cytokines and cell- surface proteins [67]. We have identified several miRNAs that in our experimental conditions were packaged into their EVs and may be characteristic of OA-EVs from these cells.
**Figure 5:** OA-EV and H-EV miRNA profiling analysis. Diagrams showing the percentages of reads from the top 5 most highly expressed miRNAs. H-EVs: EVs from control healthy MSCs; OA-EVs: EVs from OA-MSCs.

**Figure 6:** miRNA profiling of OA-EVs and their parental MSCs using NanoString technology. Heatmap showing unsupervised hierarchical clustering of significantly differentially expressed microRNAs ($p < 0.05$, $n = 124$), based on normalized digital expression counts in OA-MSC-EVs vs. OA-MSCs. Each column represents an individual sample. Relative expression changes are indicated by the colour key (red: high; blue: low). OA-MSC-EVs are depicted by grey shading, while MSC are depicted by black shading.
Table 4: microRNAs highly expressed in OA-MSCs and OA-EVs.

| Names                        | Total | microRNAs                                      |
|------------------------------|-------|------------------------------------------------|
| Shared OA-EVs & OA-MSCs      | 14    | hsa-miR-199a-3p+ hsa-miR-199b-3p               |
|                              |       | hsa-let-7a-5p                                 |
|                              |       | hsa-miR-16-5p                                 |
|                              |       | hsa-miR-21-5p                                 |
|                              |       | hsa-miR-29a-3p                                |
|                              |       | hsa-miR-29b-3p                                |
|                              |       | hsa-let-7i-5p                                 |
|                              |       | hsa-miR-4454+ hsa-miR-7975                   |
|                              |       | hsa-let-7b-5p                                 |
|                              |       | hsa-miR-221-3p                                |
|                              |       | hsa-miR-199a-5p                               |
|                              |       | hsa-miR-23a-3p                                |
|                              |       | hsa-miR-100-5p                                |
|                              |       | hsa-miR-125b-5p                               |
| OA-EVs                     | 6     | hsa-miR-142-3p                                |
|                              |       | hsa-miR-4286                                  |
|                              |       | hsa-miR-6721-5p                               |
|                              |       | hsa-miR-630                                   |
|                              |       | hsa-miR-579-3p                                |
|                              |       | hsa-miR-223-3p                                |
| OA-MSCs                    | 6     | hsa-miR-199b-5p                               |
|                              |       | hsa-miR-15a-5p                                |
|                              |       | hsa-let-7c-5p                                 |
|                              |       | hsa-miR-99a-5p                                |
|                              |       | hsa-miR-15b-5p                                |
|                              |       | hsa-let-7g-5p                                 |

Many previous studies compared miRNA expression in MSC-EVs and their parental MSCs [68–72], but these studies were all focused on healthy MSCs. Our study has identified 14 miRNAs that were highly expressed in both OA-MSC-EVs and their parental SB MSCs. These included miR-125b, which has been previously shown to regulate the expression of matrix-degrading enzymes in human chondrocytes [73–75] as well as regulate MSC osteogenesis [76], and miR-199a involved in repression of chondrogenesis [77], regulation of chondrocyte ageing and cartilage metabolism [78], and highly expressed in OA SF EVs [57]. Previous studies including ours [18, 61, 79] have described gene expression profiles of OA SB MSCs as predisposed towards bone formation and cartilage extracellular matrix regulation. The current study complements these findings by showing that highly expressed miRNA in these MSCs, including those packaged in their EVs, may be regulating cartilage homeostasis in OA. Although further functional analysis would be necessary to confirm that these miRNAs contained in the EVs may produce this chondrogenic effect.

Furthermore, the present study has identified four miRNAs that are higher-expressed in OA-MSC-EVs compared to parental MSCs and may be involved in regulating the viability and the metabolic status of OA chondrocytes. Of a particular interest are miR-142-3p previously shown to be selectively packaged into EVs [80] and miR-223-3p that have been both shown to inhibit cell apoptosis and inflammation in OA chondrocytes [81, 82], as well as miR-630 that has been earlier documented to regulate chondrogenic lineage commitment [83]. In our previous work we have used qPCR and validated the enrichment of miR-142-3p and miR-223-3p in H-EVs coming from MSCs [41]. The role of miR-630 and other miRNAs has not yet been explored in OA and is awaiting further validation.

Pathway analysis has indicated that OA-EVs and/or OA-MSCs expresses miRNAs implicated in chondrogenesis, stem cells, or other pathways related to cartilage and OA. Interestingly, “fatty acid metabolism” points out to the already known role of fatty acids in OA [84]. Also, FOXO transcription factors have been described as chondroprotectors and regulating autophagy and inflammation [85]. Altogether, these data suggest that despite their altered gene expression and predisposition to osteogenesis in OA, SB MSCs produce miRNAs and release EVs that contain miRNAs involved in positive regulation of chondrocyte viability and differentiation.

MSC-EVs from various human tissues including bone marrow (BM) and adipose tissue are beginning to be used as a therapy for OA [52, 86]. In this context, it was interesting to compare the miRNA cargo of OA-EVs with H-EVs obtained from BM aspirates from healthy individuals. Amongst top highly expressed miRNAs, 17 were shared in both types of EVs (Table 3), 13 of which were also abundant in OA-MSCs (Table 4). Common abundant miRNAs included miR-16-5p previously used as an endogenous reference gene for the normalization of urinary exosomal miRNA expression [87], and some let family members previously described amongst the top 10 most abundant miRNAs in humans’ samples [88, 89]. Common miRNAs between OA-EVs and H-EVs that were not present in OA-MSCs were earlier noted miR-142-3p and miR-630 [86] that have been described as “cartilage-protective.” Also miR-29a-3p was described as protective for cartilage [86]. Healthy EVs higher-expressed miR-145-5p (uniquely highly expressed in H-EVs compared to OA-EVs) described as having a dual role in OA [90], while OA-EVs higher-expressed hsa-miR-199a-5p involved in chondrogenesis regulation and bone formation [91], as well as highly expressed in OA SF EVs [57] and in plasma of early OA patients [92]. Our in vitro data have revealed that both H-EVs and OA-EVs marginally but significantly improved the viability of OA chondrocytes, with no difference to each other, which could be a result of consorted activity of multiple miRNAs.

Recent in vitro studies on MSC-EVs in OA have used inflammatory stimulation of chondrocytes before coculturing with H-EVs [93–96], and they obtained a reduction in the expression of chondrocyte inflammatory markers. It could be possible that this stimulation made the EV effect on chondrocytes stronger than observed in our study. In our study, we aimed to reflect more closely the in vivo conditions of chondrocytes based on our previous findings that OA chondrocytes grown in the same
conditions already present the signs of inflammation, evident by high-level expression of matrix-degrading enzymes and pro-inflammatory cytokines [18].

Even though our data on MSC-EV (both OA- and H-EVs) effects on chondrocyte gene expression are limited, they point towards a worse induction of chondrogenic gene expression by OA-EVs compared to H-EVs. The lack of statistical significance could be explained by donor-to-donor variation in both chondrocytes and EVs preparations that we have used. To minimise donor effects and generate larger EV batches for use in multiple experiments, future studies could utilise EVs [54] or chondrocytes [49] which are pooled from several donors.

Smaller than expected effects of EVs on chondrocyte gene expression could be also explained by the 3D assay conditions we used. Mortari and colleagues [49] added MSC-EVs to 4-week cultured-chondrocyte pellets and showed that EVs could diffuse into the matrix. Differently from their study, we mixed the EVs with the chondrocytes before the 3D pellet formation as investigated their effect at different time points of chondrogenesis. Also, no chondrogenic inducers such as TGFβ1 [49] were added to the media in our study because these strong inducers could “mask” or conflict with potentially smaller effects from MSC-EVs. In support of our assay design, previous studies have documented the presence of TGFβ1 in MSC-EVs [97], which could explain long-term, enhanced chondrogenic gene expression with the addition of H-EVs in our experiments. While some studies report on MSC-EV enhancement of chondrocyte collagen II expression in 2D formats [94], 3D pellets [48], cells encapsulated in cartilage-mimicking hydrogels [49] are likely to provide conditions more representative to EV traffic in vivo. Specific to OA osteochondral pathology, such constructs should take into the account intercellular distances between SB MSCs and chondrocytes, which can be established from histological studies [6, 18], as well as a known heterogeneity of chondrocyte subpopulations in OA [98, 99], which is difficult to re-capitulate in in vitro systems.

In summary, OA-EVs were capable to enhance the viability of OA chondrocytes; also, the expression of chondrogenic genes was enhanced in the chondrocytes by the EVs from OA-MSCs. However, both effects were less evident than the ones shown for H-EVs. This variation could be partially explained by the differential expression of miRNAs found in the cargo of H-EVs and OA-EVs.

5. Conclusions

The present study reports on the production, characterization and miRNA profile of EVs from SB MSCs in OA. For the first time, it shows that SB MSCs in OA are capable of producing EVs that support chondrocyte viability and chondrogenic gene expression, although future studies would be needed to confirm it using functional assays for chondrogenesis. This supports the notion that modulation of SB MSCs represents a valid strategy for endogenous cartilage regeneration in OA. This may be achieved via enhancement of their trophic activity and EV production in addition to triggering their chondrogenic differentiation, thus representing a new potential tool for cartilage regeneration.

Data Availability

miRNA profiling data are attached as supplementary files.

Disclosure

The views expressed in this article are those of the authors and not necessarily those of the BRC, NIHR, or the Department of Health and Social Care.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Xiao-nong Wang and Elena Jones are equal last authors.

Acknowledgments

We acknowledge Tracey Davey from the Newcastle University EM Research Services for the assistance with the generation of images using the Hitachi TEM (BBSRC grant reference BB/R013942/1); Anastasia Resteu from Human Dendritic Cell Lab (Institute of Cellular Medicine, Newcastle) for the assistance with Nanostring protocol; Adam Davison and Liz Strasznyski for research support services at the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM); surgeons, patients, and staff of Chapel Allerton Orthopaedic Centre; and Thomas Baboolal, Dragos Ilas, and Payal Ganguly from LIRMM for laboratory support. CSR was a beneficiary of a fellowship from Xunta de Galicia. RC and XW would like to acknowledge the support from Versus Arthritis through the Tissue Engineering and Regenerative Therapies Centre Versus Arthritis (Award 21156). Professor Pandit is a National Institute for Health Research (NIHR) Senior Investigator.

Supplementary Materials

Supplementary 1. Supplementary Figure 1: characterization of MSCs from subchondral bone (SB) of OA patients (OA-MSCs). (A) Trilineage differentiation of OA-MSCs following induction and staining with Oil Red O (day 21), Alkaline phosphatase (day 14) and Toluidine Blue (day 21), for adipogenesis, osteogenesis and chondrogenesis, respectively. (B) Phenotypic profile of OA-MSCs showing the % expression of CD73, CD90, CD105, hematopoietic-lineage markers (CD45, CD34, CD19, CD14) and HLA-DR measured by flow cytometry. Original magnification x200 for adipogenic and osteogenic and x40 for chondrogenesis.

Supplementary 2. Supplementary Figure 2: characterization of MSCs from healthy controls (H-MSCs). (A) Trilineage differentiation of H-MSCs following induction and staining with Oil Red O (day 21), Alkaline phosphatase/Von Kossa (day 14) and Alcian Blue (day 21) for adipogenesis,
osteogenesis and chondrogenesis, respectively. (B) Phenotypic profile of H-MSCs showing the % expression of CD73, CD90, CD105, hematopoietic-lineage markers (CD45, CD34, CD19, CD14) and HLA-DR measured by flow cytometry. Scale bar 200 μm for adipo- and osteogenesis and 500 μm for chondrogenesis.

**Supplementary 3.** Supplementary Data 1: analysis of miRNAs in OA-EVs compared with H-EVs, showing the differential expression, with and without FDR correction, fold change (FC) and p value.

**Supplementary 4.** Supplementary Data 2: analysis of miRNAs in OA-EVs compared with their parental MSCs, showing the differential expression, with and without FDR correction, fold change (FC) and p value.

**References**

[1] V. B. Kraus, F. J. Blanco, M. Englund, M. A. Karsdal, and L. S. Lohmander, "Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use," *Osteoarthritis and Cartilage*, vol. 23, no. 8, pp. 1233–1241, 2015.

[2] A. Mobasheri, G. Kalamegam, G. Musumeci, and M. E. Batt, "Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritic related orthopaedic conditions," *Maturitas*, vol. 78, no. 3, pp. 188–198, 2014.

[3] L. Kock, C. C. van Donkelaar, and K. Ito, “Tissue engineering of functional articular cartilage: the current status,” *Cell and Tissue Research*, vol. 347, no. 3, pp. 613–627, 2012.

[4] S. Safiri, A. A. Kolahi, E. Smith et al., "Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the global burden of disease study 2017," *Annals of the Rheumatic Diseases*, vol. 79, no. 6, pp. 819–828, 2020.

[5] H. Fang, L. Huang, I. Welch et al., "Early changes of articular cartilage and subchondral bone in the DMM mouse model of osteoarthritis," *Scientific Reports*, vol. 8, no. 1, p. 2855, 2018.

[6] D. M. Findlay and G. J. Atkins, "Osteoblast-chondrocyte interactions in osteoarthritis," *Current Osteoporosis Reports*, vol. 12, no. 1, pp. 127–134, 2014.

[7] B. J. E. de Lange-Broekaar, A. Ioan-Facsinay, G. J. V. M. van Osch et al., "Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review," *Osteoarthritis and Cartilage*, vol. 20, no. 12, pp. 1484–1499, 2012.

[8] C. R. Scanzello and S. R. Goldring, "The role of synovitis in osteoarthritis pathogenesis," *Bone*, vol. 51, no. 2, pp. 249–257, 2012.

[9] C. Sanchez, M. A. Deberg, N. Piccardi, P. Msika, J. Y. L. Reginster, and Y. E. Henrotin, "Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1β and oncostatin M pre-treated non-sclerotic osteoblasts," *Osteoarthritis and Cartilage*, vol. 13, no. 11, pp. 979–987, 2005.

[10] C. Sanchez, M. A. Deberg, N. Piccardi, P. Msika, J. Y. L. Reginster, and Y. E. Henrotin, "Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes," *Osteoarthritis and Cartilage*, vol. 13, no. 11, pp. 988–997, 2005.

[11] M. Stock, S. Menges, N. Eitzinger et al., "A Dual Role of Upper Zone of Growth Plate and Cartilage Matrix–Associated Protein in Human and Mouse Osteoarthritic Cartilage: Inhibition of Aggrecanases and Promotion of Bone Turnover," *Arthritis & Rheumatology*, vol. 69, no. 6, pp. 1233–1245, 2017.

[12] A. R. Sharma, S. Jagga, S. S. Lee, and J. S. Nam, "Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis," *International Journal of Molecular Sciences*, vol. 14, no. 10, pp. 19805–19830, 2013.

[13] Y. Hu, X. Chen, S. Wang, Y. Jing, and J. Su, "Subchondral bone microenvironment in osteoarthritis and pain," *Bone Res*, vol. 9, no. 1, p. 20, 2021.

[14] R. K. Zhang, G. W. Li, C. Zeng et al., "Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGFB1)," *Bone Joint Res*, vol. 7, no. 11, pp. 587–594, 2018.

[15] D. M. Findlay and J. S. Kuliwaba, "Bone-cartilage crosstalk: a conversation for understanding osteoarthritis," *Bone Research*, vol. 4, no. 1, p. 16028, 2016.

[16] D. B. Burr and E. L. Radin, "Microfractures and microcracks in subchondral bone: are they relevant to osteoarthritis?," *Rheumatic Diseases Clinics of North America*, vol. 29, no. 4, pp. 675–685, 2003.

[17] W. Hu, Y. Chen, C. Dou, and S. Dong, "Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis," *Annals of the Rheumatic Diseases*, vol. 80, no. 4, pp. 413–422, 2020.

[18] C. Sanjurjo-Rodriguez, T. G. Baboolal, A. N. Burska et al., "Gene expression and functional comparison between multipotential stromal cells from lateral and medial condyles of knee osteoarthritic patients," *Scientific Reports*, vol. 9, no. 1, p. 9321, 2019.

[19] H. J. Knowles, L. Moskovsky, M. S. Thompson et al., "Chondroclasts are mature osteoclasts which are capable of cartilage matrix resorption," *Virchows Archiv*, vol. 461, no. 2, pp. 205–210, 2012.

[20] R. E. Miller, P. B. Tran, A. M. Obeidat et al., "The role of peripheral nociceptive neurons in the pathophysiology of osteoarthritis pain," *Current Osteoporosis Reports*, vol. 13, no. 5, pp. 318–326, 2015.

[21] A. Eitner, G. O. Hofmann, and H. G. Schäible, "Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models," *Frontiers in Molecular Neuroscience*, vol. 10, p. 349, 2017.

[22] C. Sanchez, G. Mazzucchelli, C. Lambert, F. Comblain, E. DePauw, and Y. Henrotin, "Comparison of secretome from osteoblasts derived from sclerotic versus non-sclerotic subchondral bone in OA: a pilot study," *PLoS One*, vol. 13, no. 3, article e0194591, 2018.

[23] M. Shabestari, Y. R. Shabestari, M. A. Landin et al., "Altered protein levels in bone marrow lesions of hip osteoarthritis: analysis by proteomics and multiplex immunoassays," *International Journal of Rheumatic Diseases*, vol. 23, no. 6, pp. 788–799, 2020.

[24] S. Miyaki and M. K. Lotz, "Extracellular vesicles in cartilage homeostasis and osteoarthritis," *Current Opinion in Rheumatology*, vol. 30, no. 1, pp. 129–135, 2018.

[25] C. Théry, K. W. Witwer, A. Aikawa et al., "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines," *Journal of Extracellular Vesicles*, vol. 7, no. 1, p. 1535750, 2018.
functions: a position statement from the International Society for Extracellular Vesicles, *Journal of Extracellular Vesicles*, vol. 3, no. 1, p. 26913, 2014.

[27] L. M. Doyle and M. Wang, "Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis," *Cell*, vol. 8, no. 7, p. 727, 2019.

[28] R. C. Lai, R. W. Y. Yeo, and S. K. Lim, "Mesenchymal stem cell exosomes," *Seminars in Cell & Developmental Biology*, vol. 40, pp. 82–88, 2015.

[29] X. Liang, Y. Ding, Y. Zhang, H. F. Tse, and Q. Lian, "Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives," *Cell Transplantation*, vol. 23, no. 9, pp. 1045–1059, 2014.

[30] M. P. Mycko and S. E. Baranzini, "microRNA and exosome profiling in multiple sclerosis," *Multiple Sclerosis*, vol. 26, no. 5, pp. 599–604, 2020.

[31] N. Dilsiz, "Role of exosomes and exosomal micro RNAs in cancer," *Future Science OA*, vol. 6, article FSO465, 2020.

[32] Z. Li, Y. Wang, K. Xiao, S. Xiang, Z. Li, and X. Weng, "Emerging role of Exosomes in the joint diseases," *Cellular Physiology and Biochemistry*, vol. 47, no. 5, pp. 2008–2017, 2018.

[33] S. Cosenza, M. Ruiz, M. Maumus, C. Jorgensen, and D. Noel, "Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles," *International Journal of Molecular Sciences*, vol. 18, no. 4, p. 889, 2017.

[34] S. Asghar, G. J. Litherland, J. C. Lockhart, C. S. Goodyear, and A. Crilly, "Exosomes in intercellular communication and implications for osteoarthritis," *Rheumatology (Oxford)*, vol. 59, no. 1, pp. 57–68, 2020.

[35] A. Esa, K. D. Connolly, R. Williams, and C. W. Archer, "Extra- cellular vesicles in the synovial joint: is there a role in the pathophysiology of osteoarthritis?," *Malaysian Orthopaedic Journal*, vol. 13, no. 1, pp. 1–7, 2019.

[36] J. Withrow, C. Murphy, Y. Liu, M. Hunter, S. Fulzele, and M. W. Hamrick, "Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis," *Arthritis Research & Therapy*, vol. 18, no. 1, p. 286, 2016.

[37] Z. Ni, S. Zhou, S. Li et al., "Exosomes: roles and therapeutic potential in osteoarthritis," *Bone Research*, vol. 8, no. 1, p. 25, 2020.

[38] C. Lin, L. Liu, C. Zeng et al., "Activation of mTORC1 in sub- chondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12," *Bone Research*, vol. 7, no. 1, p. 5, 2019.

[39] M. Cucchiari, L. de Girolamo, G. Filardo et al., "Basic science of osteoarthritis," *Exp Orthop*, vol. 3, no. 1, p. 22, 2016.

[40] B. L. Wise, J. Niu, M. Yang et al., "Patterns of compartment involvement in tibiofemoral osteoarthritis in men and women and in whites and African Americans," *Arthritis Care & Research*, vol. 64, no. 6, pp. 847–852, 2012.

[41] M. Reis, E. Mavin, L. Nicholson, K. Green, A. M. Dickinson, and X. N. Wang, "Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function," *Frontiers in Immunology*, vol. 9, p. 2538, 2018.

[42] M. Dominici, K. le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.

[43] C. Qing, C. Wei-ding, and F. Wei-min, "Co-culture of chondrocytes and bone marrow mesenchymal stem cells in vitro enhances the expression of cartilaginous extracellular matrix components," *Brazilian Journal of Medical and Biological Research*, vol. 44, no. 4, pp. 303–310, 2011.

[44] C. Sticht, C. de la Torre, A. Parveen, and N. Grett, "miRWalk: An online resource for prediction of microRNA binding sites," *PLoS One*, vol. 13, no. 10, article e0206239, 2018.

[45] I. S. Vlahos, K. Zagganas, M. D. Paraskevopoulos et al., "DIANA-miPath v3.0: deciphering microRNA function with experimental support," *Nucleic Acids Research*, vol. 43, no. W1, pp. W460–W466, 2015.

[46] B. Jassal, L. Matthews, G. Viteri et al., "The reactome pathway knowledgebase," *Nucleic Acids Research*, vol. 48, no. D1, pp. D498–D503, 2020.

[47] T. Tokar, C. Pastrello, A. E. M. Rossos et al., "mirDIP 4.1-integrative database of human microRNA target predictions," *Nucleic Acids Research*, vol. 46, no. D1, pp. D360–D370, 2018.

[48] H. Kim, D. Kang, Y. Cho, and J. H. Kim, "Epigenetic regulation of chondrocyte catabolism and anabolism in osteoarthritis," *Molecules and Cells*, vol. 38, no. 8, pp. 677–684, 2015.

[49] L. Mortati, L. de Girolamo, C. Perucca Orfei et al., "In Vitro Study of Extracellular Vesicles Migration in Cartilage-Derived Osteoarthritis Samples Using Real-Time Quantitative Multimodal Nonlinear Optics Imaging," *Pharmaceutics*, vol. 12, no. 8, p. 734, 2020.

[50] H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono, and M. Kanehisa, "KEGG: Kyoto encyclopedia of genes and genomes," *Nucleic Acids Research*, vol. 27, no. 1, pp. 29–34, 1999.

[51] J. Malda, J. Boere, C. H. A. van de Lest, P. R. van Weeren, and M. H. M. Wauben, "Extracellular vesicles – new tool for joint repair and regeneration," *Nature Reviews Rheumatology*, vol. 12, no. 4, pp. 243–249, 2016.

[52] J. J. Li, E. Hosseini-Beheshti, G. Grau, H. Zreiqat, and C. Little, "Stem Cell-Derived Extracellular Vesicles for Treating Joint Injury and Osteoarthritis," *Nanomaterials* (Basel), vol. 9, no. 2, p. 261, 2019.

[53] R. Domenis, R. Zanutel, F. Caponnetto et al., "Characterization of the Proinflammatory profile of synovial fluid-derived Exosomes of patients with osteoarthritis," *Mediators of Inflammation*, vol. 2017, Article ID 4814987, 11 pages, 2017.

[54] K. Gao, W. Zhu, H. Li et al., "Association between cytokines and exosomes in synovial fluid of individuals with knee osteoarthritis," *Modern Rheumatology*, vol. 30, no. 4, pp. 758–764, 2020.

[55] R. Kolhe, M. Hunter, S. Liu et al., "Gender-specific differential expression of exosomal miRNA in synovial fluid of patients with osteoarthritis," *Scientific Reports*, vol. 7, no. 1, p. 2029, 2017.

[56] R. Kolhe, V. Owens, A. Sharma et al., "Sex-specific differences in extracellular vesicle protein cargo in synovial fluid of patients with osteoarthritis," *Life (Basel)*, vol. 10, no. 12, p. 337, 2020.

[57] O. H. Jeon, D. R. Wilson, C. C. Clement et al., "Senescence cell-associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers," *JCI Insight*, vol. 4, no. 7, 2019.

[58] H. L. Stewart, C. E. Kawcak, "The importance of Subchondral bone in the pathophysiology of osteoarthritis," *Front Vet Sci*, vol. 5, p. 178, 2018.

[59] T. Hüge and J. Geurts, "What drives osteoarthritis?-synovial versus subchondral bone pathology," *Rheumatology (Oxford)*, vol. 56, no. 9, pp. 1461–1471, 2017.
T. R. Coughlin and O. D. Kennedy, "The role of subchondral bone damage in post-traumatic osteoarthritis," *Annals of the New York Academy of Sciences*, vol. 1383, no. 1, pp. 58–66, 2016.

T. M. Campbell, S. M. Churchman, A. Gomez et al., "Mesenchymal stem cell alterations in bone marrow lesions in patients with hip osteoarthritis," *Arthritis & Rheumatology*, vol. 68, no. 7, pp. 1648–1659, 2016.

M. A. Karsdal, A. C. Bay-Jensen, R. J. Lories et al., "The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?", *Annals of the Rheumatic Diseases*, vol. 73, no. 2, pp. 336–348, 2014.

J. J. el-Jawhari, P. Ganguly, E. Jones, and P. V. Giannoudis, "Bone marrow multipotent Mesenchymal stromal cells as autologous therapy for osteonecrosis: effects of age and underlying causes," *Bioengineering (Basel)*, vol. 8, no. 5, p. 69, 2021.

M. Mahmoud, N. Abu-Shabha, O. Azmy, and N. El-Badri, "Impact of diabetes mellitus on human Mesenchymal stromal cell biology and functionality: implications for autologous transplantation," *Stem Cell Reviews and Reports*, vol. 15, no. 2, pp. 194–217, 2019.

F. C. Cassidy, C. Shortiss, C. G. Murphy et al., "Impact of type 2 diabetes mellitus on human bone marrow stromal cell number and phenotypic characteristics," *International Journal of Molecular Sciences*, vol. 21, no. 7, p. 2476, 2020.

P. Li, M. Kaslan, S. H. Lee, J. Yao, and Z. Gao, "Progress in exosome isolation techniques," *Theranostics*, vol. 7, no. 3, pp. 789–804, 2017.

R. Kalluri and V. S. LeBleu, "The biology,function,and biomedical applications of exosomes," *Science*, vol. 367, no. 6478, p. eaau6977, 2020.

Y. Nakamura, S. Miyaki, H. Ishitobi et al., "Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration," *FEBS Letters*, vol. 589, no. 11, pp. 1257–1265, 2015.

D. G. Phinney, M. di Giuseppe, J. Najah et al., "Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuffle microRNAs," *Nature Communications*, vol. 6, no. 1, p. 8472, 2015.

S. R. Baglio, K. Rooijers, D. Koppers-Lalic et al., "Human bone-marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species," *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 127, 2015.

F. Collino, M. C. Deregibus, S. Bruno et al., "Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs," *PloS One*, vol. 5, no. 7, article e11803, 2010.

X. Y. Zou, Y. Yu, S. Lin et al., "Comprehensive miRNA analysis of human umbilical cord-derived Mesenchymal stromal cells and extracellular vesicles," *Kidney & Blood Pressure Research*, vol. 43, no. 1, pp. 152–161, 2018.

T. Matsukawa, T. Sakai, T. Yonezawa et al., "MicroRNA-125b regulates the expression of aggrecanase-1 (ADAMTS-4) in human osteoarthritic chondrocytes," *Arthritis Research & Therapy*, vol. 15, no. 1, p. R28, 2013.

N. Xu, L. Zhang, F. Meisgen et al., "MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion," *The Journal of Biological Chemistry*, vol. 287, no. 35, pp. 29899–29908, 2012.

Z. Rasheed, N. Rasheed, W. A. Abdulmonem, and M. I. Khan, "MicroRNA-125b-5p regulates IL-1β induced inflammatory genes via targeting TRAF6-mediated MAPKs and NF-kB signaling in human osteoarthritic chondrocytes," *Scientific Reports*, vol. 9, no. 1, p. 6882, 2019.

Y. Mizuno, K. Yagi, Y. Tokuzawa et al., "miR-125b inhibits osteoclastic differentiation by down-regulation of cell proliferation," *Biochemical and Biophysical Research Communications*, vol. 368, no. 2, pp. 267–272, 2008.

E. A. Lin, L. Kong, X. H. Bai, Y. Luan, and C. J. Liu, "miR-199a, a Bone Morphogenic Protein 2-responsive MicroRNA, Regulates Chondrogenesis via Direct Targeting to Smad1," *The Journal of Biological Chemistry*, vol. 284, no. 17, pp. 11326–11335, 2009.

T. Ukai, M. Sato, H. Akutsu, A. Umezawa, and J. Mochida, "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism," *Journal of Orthopaedic Research*, vol. 30, no. 12, pp. 1915–1922, 2012.

D. C. Illas, S. M. Churchman, T. Baboolal et al., "The simultaneous analysis of mesenchymal stem cells and early osteocytes accumulation in osteoarthritic femoral head sclerotic bone," *Rheumatology (Oxford)*, vol. 58, no. 10, pp. 1777–1783, 2019.

J. Guduric-Fuchs, A. O’Connor, B. Camp, C. L. O’Neill, R. J. Medina, and D. A. Simpson, "Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types," *BMC Genomics*, vol. 13, no. 1, p. 357, 2012.

X. Wang, Y. Guo, C. Wang, H. Yu, X. Yu, and H. Yu, "MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1," *Inflammation*, vol. 39, no. 5, pp. 1718–1728, 2016.

H. C. Dong, P. N. Li, C. J. Chen et al., "Serine/lysine attenuates cartilage degeneration by regulating miR-223-3p/NLRP3 Inflammosome signaling," *Inflammation*, vol. 42, no. 4, pp. 1265–1275, 2019.

B. Bakhshandeh, M. Soleimani, S. H. Paylakhi, and N. Ghaemi, "A microRNA signature associated with chondrogenic lineage commitment," *Journal of Genetics*, vol. 91, no. 2, pp. 171–182, 2012.

M. Loef, J. W. Schoones, M. Kloppenburg, and A. Joan-Fasci, "Fatty acids and osteoarthritis: different types, different effects," *Joint, Bone, Spine*, vol. 86, no. 4, pp. 451–458, 2019.

T. Matsuzaki, O. Alvarez-Garcia, S. Mokuda et al., "FoxO transcription factors modulate autophagy and proteoglycan 4 in cartilage homeostasis and osteoarthritis," *Science Translational Medicine*, vol. 10, no. 428, p. eaan0746, 2018.

E. Ragni, C. Perucca Orfei, P. de Luca, A. Colombini, M. Viganò, and L. de Girolamo, "Selective extracellular vesicles orchestrate the healing capacity of adipose Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis, miRNA repertoire revealed by next-generation sequencing of human umbilical cord-derived Mesenchymal stem cells," *Stem Cells Translational Medicine*, vol. 3, no. 1, pp. 101–108, 2014.
ocular tissues by miRNA-Seq.” Investigative Ophthalmology & Visual Science, vol. 57, no. 8, pp. 3731–3739, 2016.

[90] M. Nugent, “MicroRNAs: exploring new horizons in osteoarthritis,” Osteoarthritis and Cartilage, vol. 24, no. 4, pp. 573–580, 2016.

[91] J. B. van Meurs, C. G. Boer, L. Lopez-Delgado, and J. A. Riancho, “Role of Epigenomics in bone and cartilage disease,” Journal of Bone and Mineral Research, vol. 34, no. 2, pp. 215–230, 2019.

[92] S. A. Ali, R. Gandhi, P. Potla et al., “Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee osteoarthritis,” Osteoarthritis and Cartilage, vol. 28, no. 11, pp. 1471–1481, 2020.

[93] C. Cavallo, G. Merli, R. M. Borzi et al., “Small extracellular vesicles from adipose derived stromal cells significantly attenuate in vitro the NF-κB dependent inflammatory/catabolic environment of osteoarthritis,” Scientific Reports, vol. 11, no. 1, p. 1053, 2021.

[94] S. Li, S. Stöckl, C. Lukas et al., “hBMSC-derived extracellular vesicles attenuate IL-1β-induced catabolic effects on OA-chondrocytes by regulating pro-inflammatory signaling pathways,” Frontiers in Bioengineering and Biotechnology, vol. 8, p. 603598, 2020.

[95] S. Zhang, K. Y. W. Teo, S. J. Chuah, R. C. Lai, S. K. Lim, and W. S. Toh, “MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis,” Biomaterials, vol. 200, pp. 35–47, 2019.

[96] C. H. Woo, H. K. Kim, G. Y. Jung et al., “Small extracellular vesicles from human adipose-derived stem cells attenuate cartilage degeneration,” Journal of Extracellular Vesicles, vol. 9, no. 1, p. 1735249, 2020.

[97] M. Ruiz, K. Toupet, M. Maumus, P. Rozier, C. Jorgensen, and D. Noël, “TGFBI secreted by mesenchymal stromal cells ameliorates osteoarthritis and is detected in extracellular vesicles,” Biomaterials, vol. 226, p. 119544, 2020.

[98] Q. Ji, Y. Zheng, G. Zhang et al., “Single-cell RNA-seq analysis reveals the progression of human osteoarthritis,” Annals of the Rheumatic Diseases, vol. 78, no. 1, pp. 100–110, 2019.

[99] C. H. Chou, V. Jain, J. Gibson et al., “Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis,” Scientific Reports, vol. 10, no. 1, p. 10868, 2020.